Skip to content
Screener

Aclaris Therapeutics ACRS Single Reportable — Licensing Expenses

Similar metrics at other companies

Alumis Inc. logo
ALMSSingle Reportable — Operating Expenses
$100.15M-15.8%
LQD
LQDASingle Reportable — Program Expenses
$21.66M+64.4%
Dogwood Therapeutics logo
DWTXSingle Reportable — Operating Expenses
$5.08M+14.6%
El Pollo Loco logo
LOCOSingle Reportable — Occupancy Expenses
$7.95M-2.0%
El Pollo Loco logo
LOCOSingle Reportable — Other Expenses
$19.37M+4.0%
Iovance Biotherapeutics, Inc. logo
IOVASingle Reportable — Operating Expenses
$103.03M-16.0%

Other financials

Income statement

See full
Revenue$1.6M-8.3%
Gross profit$1.4M+11.8%
Operating income-$24.2M-31.7%
Net income-$21.5M-39.4%
EPS (diluted)-$0.15-15.4%

Balance sheet

See full
Cash & equivalents$19.2M-24.5%
Total debt$1.9M-21.8%
Total equity$124.6M-5.4%
Total assets$179.7M-5.0%

Cash flow

See full
Operating cash flow-$19.8M-98.6%
CapEx$58.0K+176%
Free cash flow-$19.9M-98.8%

Valuation

See full
Market cap$868.56M+389%
Enterprise value$851.24M+451%
P/S105.7×+95.1×

Profitability

See full
Gross margin79.5%-6.3pp
Operating margin-1,050.2%+266pp
Net margin-921.5%+161pp
FCF margin-756.5%

Returns & leverage

See full
Return on equity-59.1%-17.4pp
Debt / equity0.0×
Current ratio3.5×-0.4×

Where this comes from

Reported directly by Aclaris Therapeutics in its filing.

Tagged under the XBRL concept acrs:LicensingExpenses.

The source filing: Aclaris Therapeutics’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:31 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001104659-26-092065
(In thousands)Three Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Other research and development(2)1,3981,4623,2972,962
Total research and development18,06611,44933,72323,033
General and administrative(3)6,0485,38612,79111,525
Licensing1,2351,3352,6282,345
Revaluation of contingent consideration3001,5003001,800
Segment operating loss$(24,238)$(18,408)$(46,430)$(36,492)
Other income2,7332,9795,1015,978
Segment loss before income taxes$(21,505)$(15,429)$(41,329)$(30,514)

Item 1. Financial Statements

FAQ

What is Aclaris Therapeutics's single reportable — licensing expenses?
Aclaris Therapeutics (ACRS) reported single reportable — licensing expenses of $1.24M in Q2 2026.
How has Aclaris Therapeutics's single reportable — licensing expenses changed year-over-year?
Aclaris Therapeutics's single reportable — licensing expenses decreased by 7.5% year-over-year, from $1.34M to $1.24M.
What does single reportable — licensing expenses mean?
Captures the costs associated with acquiring or maintaining licenses for intellectual property, technologies, or drug candidates from third parties. These expenses are vital for companies that rely on external innovation to supplement their internal research pipeline. It reflects the strategic cost of accessing external scientific assets.

Ask your AI about Aclaris Therapeutics's single reportable — licensing expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude